Viridian Therapeutics, Inc. $VRDN Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lessened its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 5.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 509,959 shares of the company’s stock after selling 27,065 shares during the period. Fisher Asset Management LLC’s holdings in Viridian Therapeutics were worth $7,129,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in Viridian Therapeutics by 33.8% during the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after purchasing an additional 310,998 shares during the last quarter. Paradigm Biocapital Advisors LP grew its stake in shares of Viridian Therapeutics by 15.1% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 2,095,079 shares of the company’s stock valued at $28,242,000 after buying an additional 275,000 shares during the period. Nuveen LLC purchased a new stake in shares of Viridian Therapeutics in the 1st quarter valued at approximately $3,352,000. Affinity Asset Advisors LLC increased its holdings in shares of Viridian Therapeutics by 144.3% during the 1st quarter. Affinity Asset Advisors LLC now owns 390,000 shares of the company’s stock worth $5,257,000 after buying an additional 230,386 shares during the last quarter. Finally, Exome Asset Management LLC purchased a new stake in shares of Viridian Therapeutics during the 1st quarter valued at approximately $2,929,000.

Wall Street Analyst Weigh In

A number of research firms recently commented on VRDN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Wednesday, October 8th. William Blair assumed coverage on Viridian Therapeutics in a research report on Wednesday. They issued an “outperform” rating on the stock. Jefferies Financial Group assumed coverage on Viridian Therapeutics in a research note on Monday, August 25th. They issued a “buy” rating and a $44.00 price target on the stock. Oppenheimer raised their price objective on Viridian Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Finally, Wells Fargo & Company reduced their price objective on shares of Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a report on Thursday, August 7th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.55.

Viridian Therapeutics Stock Performance

Shares of Viridian Therapeutics stock opened at $32.46 on Friday. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of -10.75 and a beta of 0.87. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.28 and a quick ratio of 11.28. The business has a 50-day moving average of $25.47 and a 200 day moving average of $19.77. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $33.34.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.48. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. The company had revenue of $70.57 million for the quarter, compared to analyst estimates of $16.21 million. Viridian Therapeutics’s revenue for the quarter was up 81993.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc purchased 454,545 shares of the firm’s stock in a transaction on Thursday, October 23rd. The stock was bought at an average price of $22.00 per share, with a total value of $9,999,990.00. Following the transaction, the director directly owned 3,914,458 shares of the company’s stock, valued at approximately $86,118,076. This represents a 13.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.58% of the stock is currently owned by company insiders.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.